Patent ID: 9464072
Filing Date: 2016-10-11
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A method for treating a patient suffering from a glucocorticoid-related central nervous system disorder, comprising administering to the patient an effective amount of a selective inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity, wherein the disorder is selected from the group consisting of Alzheimer's disease, decline in cognitive function in Alzheimer's disease and associated dementias, cognitive deficits associated with aging and neurodegeneration, dementia, senile dementia, AIDS dementia, depression, anxiety, panic disorder, post traumatic stress disorder, steroid-induced acute psychosis, cognitive deficits associated with diabetes, attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), mild cognitive impairment, and schizophrenia, and wherein the inhibitor is a compound of formula (IV) wherein: n is 2; R each of which is independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, Cl, Br, F, I, —CN, —NO R R R R R R R m is 1; or a pharmaceutically acceptable salt thereof, or a combination thereof.